THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
There's no shortage of cancer immunotherapies ... Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...
Clinical Trials Arena on MSN7d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
Helping Libtayo reach its potential was a 2022 nod to treat newly diagnosed non-small cell lung cancer (NSCLC), allowing it to compete with Merck’s powerhouse PD-1 drug Keytruda. More growth ...
Libtayo is designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation and already holds approvals to treat certain patients with advanced CSCC. C-POST met its primary ...
Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback